SITC is the first and only organization dedicated to cancer immunotherapy to be accepted as a formal member of the Commission on Cancer (CoC), a program of the American College of Surgeons.
The CoC is the nation’s leading accreditation body for cancer care and has established a strong partnership approach to defining and measuring quality as it relates to managing patients with cancer. Today, more than 80 percent of Americans with cancer will seek treatment at a CoC accredited facility.
SITC represents leaders of the field of cancer immunotherapy, to help establish and implement immunotherapy at CoC-accredited institutions and develop mechanisms for collecting data and educating healthcare providers on the optimal way to deliver immunotherapy. SITC Immediate Past President, Howard Kaufman, MD, FACS, of the Rutgers Cancer Institute of New Jersey, serves as SITC’s official liaison to the Commission.